CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(1):191-193.   Published online 2022 November 22    DOI: https://doi.org/10.3350/cmh.2022.0410

Excel Download

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Clinical and Molecular Hepatology. 2023;29(1):191-193   Crossref logo
Link1 Link2 Link3

770 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBsAg LOSS IN HBeAg NEGATIVE CHB PATIENTS: FOLLOW-UP OF LONG TERM RESPONDERS
Journal of Hepatology. 2013;58:S313-S314   Crossref logo
Link1 Link2

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
Clinical and Molecular Hepatology. 2023;29(1):146-162   Crossref logo
Link1 Link2 Link3

THU-222-The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos (t)ide analogues
Journal of Hepatology. 2019;70(1):e262-e263   Crossref logo
Link1 Link2

PS-055-The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal
Journal of Hepatology. 2019;70(1):e33-e34   Crossref logo
Link1 Link2

Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice?
Journal of Hepatology. 2018;68:S513-S514   Crossref logo
Link1 Link2

745 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBSAG LOSS OR SERO-CONVERSION IN HBEAG NEGATIVE CHB PATIENTS: EXPERIENCE FROM FOUR REFERRAL CENTERS IN GERMANY
Journal of Hepatology. 2011;54:S299-S300   Crossref logo
Link1 Link2

Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels
Journal of Hepatology. 2022;77(4):1223-1224   Crossref logo
Link1 Link2

Early Serum HBV RNA Level in Combination With the HBeAg Response Can Effectively Predict the HBeAg Response in Patients on Nucleos(t)ide Analogue Therapy (ClinicalTrials.gov (NCT03909191)
. 2021;   Crossref logo
Link1 Link2

Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study
Journal of Hepatology. 2020;73:S49-S50   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.